Loading stock data…
AMRX
$14.69+0.98 (+7.15%)
After Hours$14.92+0.23 (+1.57%)· Last close Jun 9
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internationally.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Amneal Pharmaceuticals, Inc. in the Healthcare sector is trading at $14.69. Wall Street consensus targets $17.20 (5 analysts), implying a +17.1% move over the next 12 months. The stock is currently near its 52-week high of $15.42, remaining 20.9% above its 200-day moving average. On fundamentals, Piotroski 7/9 indicates strong financial quality, Altman Z in the distress zone. The Whystock Score of 95/100 reflects bullish alignment across trend, valuation and analyst targets.
Ecosystem Influences
Sell-side targets imply +17.1% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$14.69
Potential Downside
0%
Whystock Fair Value$14.69
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Fundamentals
Amneal Pharmaceuticals, Inc., a global biopharmaceutical company, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products in the United States, India, Ireland, and internation...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-268.92%
Volume
Today's trading volume
2.27M
Recent News
Amneal Pharmaceuticals Bets on Biosimilars, Patches to Power Next Growth Phase
Amneal Pharmaceuticals (NASDAQ:AMRX) Co-Founder, President and Co-Chief Executive Officer Chirag Patel said the company is entering a stronger growth phase, driven by momentum in its existing generics portfolio, a newly expanded biosimilars platform and specialty product launches. Speaking at a Gol
How The Amneal Pharmaceuticals (AMRX) Story Is Shifting With Biosimilars And 2026 Expectations
Amneal Pharmaceuticals is back in focus after analysts lifted their price target to US$16.00, alongside a fair value estimate now set at US$17.20. The update leans heavily on views around the latest Q1 report and expectations for biosimilar opportunities, while still flagging risks tied to execution and the fiscal 2026 outlook. In the sections that follow, you will see how the bullish and bearish threads in this evolving narrative could matter for your own research process. Analyst Price...
Amneal Stock Up on FDA Nod for Romidepsin Injection Solution
AMRX gains after FDA approval of ready-to-use romidepsin injection, with 180-day exclusivity and a potential boost to its injectables portfolio.
Why Amneal (AMRX) Stock Is Trading Up Today
Shares of pharmaceutical company Amneal Pharmaceuticals (NASDAQ:AMRX) jumped 5.7% in the afternoon session after the U.S. Food and Drug Administration (FDA) approved its romidepsin injection solution, a treatment used in certain lymphoma patients.
3 Profitable Stocks with Open Questions
Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a business is in the green today doesn’t mean it will thrive tomorrow.